FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109966464> ?p ?o ?g. }

• W2109966464 endingPage "153" @default.
• W2109966464 startingPage "145" @default.
• W2109966464 abstract "ABSTRACT Objective: Ischemic angiogenesis is dependent on vascular nitric oxide (NO) bioavailability, in part by reducing matrix metalloproteinases (MMP)‐2 and ‐9 activity and angiostatin production. In the metabolic syndrome, the authors have demonstrated that reduced skeletal muscle microvessel density (SKMVD) was correlated with chronic reductions in NO bioavailability, but these relationships are complicated by the presence of the multiple pathological states inherent in the metabolic syndrome. Given this, the authors hypothesized that low NO bioavailability could reduce SKMVD in normal rats, independent of any systemic pathologies associated with the metabolic syndrome, and that this would be correlated with increased angiostatin production. Methods: Rats were separated into 3 groups: (1) control, (2) chronic NOS inhibition (10 −4 M L‐NAME; drinking water), and (3) NOS inhibition/normotensive (combined L‐NAME/hydralazine treatment; 50 mg/kg/d; drinking water). Vessel structure, reactivity, and NO bioavailability were assessed in isolated vessels using standard techniques. SKMVD was determined using established immunohistochemical methods. Established protein analyses were performed for MMP‐2 and MMP‐9 expression/activity and for angiostatin expression. Alterations in vascular endothelial growth factor (VEGF) levels under the conditions of the study were assessed using ELISA. Results: After 6 weeks, MAP was elevated in L‐NAME rats vs. control, although this difference was abolished in L‐NAME/hydralazine rats. NOS inhibition abrogated dilation to acetylcholine and arterial eNOS activity. While NOS inhibition reduced SKMVD vs. control, hydralazine treatment did not improve density, suggesting that rarefaction in NOS‐inhibited rats was independent of elevated pressure. Skeletal muscle demonstrated reduced active hyperemia and increased minimum vascular resistance in L‐NAME rats, which was also associated with increased arteriolar wall stiffness. L‐NAME/hydralazine treatment, while still causing an elevated resistance, prevented arteriolar wall stiffening. Protein analysis demonstrated that neither expressions nor activities of MMP‐2 or MMP‐9 were altered from control in skeletal muscle of rats treated with L‐NAME and angiostatin production was not altered in any group. Chronic NOS inhibition was associated with no consistent change in plasma VEGF levels. Conclusions: These results suggest that a reduced SKMVD develops with low NO bioavailability, although this process was not associated with significant alterations to either VEGF or angiostatin production." @default.
• W2109966464 created "2016-06-24" @default.
• W2109966464 creator A5000886546 @default.
• W2109966464 creator A5021166340 @default.
• W2109966464 creator A5051594076 @default.
• W2109966464 date "2007-02-01" @default.
• W2109966464 modified "2023-10-11" @default.
• W2109966464 title "Angiostatin Does Not Contribute to Skeletal Muscle Microvascular Rarefaction with Low Nitric Oxide Bioavailability" @default.
• W2109966464 cites W1957992664 @default.
• W2109966464 cites W1967923917 @default.
• W2109966464 cites W1985112972 @default.
• W2109966464 cites W1985641253 @default.
• W2109966464 cites W2011053169 @default.
• W2109966464 cites W2023034468 @default.
• W2109966464 cites W2025245180 @default.
• W2109966464 cites W2041218674 @default.
• W2109966464 cites W2044538776 @default.
• W2109966464 cites W2060233663 @default.
• W2109966464 cites W2068602341 @default.
• W2109966464 cites W2068801993 @default.
• W2109966464 cites W2076363657 @default.
• W2109966464 cites W2105847945 @default.
• W2109966464 cites W2116844483 @default.
• W2109966464 cites W2122344654 @default.
• W2109966464 cites W2140063079 @default.
• W2109966464 cites W2147770931 @default.
• W2109966464 cites W3190460761 @default.
• W2109966464 doi "https://doi.org/10.1080/10739680601131242" @default.
• W2109966464 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17365669" @default.
• W2109966464 hasPublicationYear "2007" @default.
• W2109966464 type Work @default.
• W2109966464 sameAs 2109966464 @default.
• W2109966464 citedByCount "8" @default.
• W2109966464 countsByYear W21099664642012 @default.
• W2109966464 countsByYear W21099664642016 @default.
• W2109966464 countsByYear W21099664642023 @default.
• W2109966464 crossrefType "journal-article" @default.
• W2109966464 hasAuthorship W2109966464A5000886546 @default.
• W2109966464 hasAuthorship W2109966464A5021166340 @default.
• W2109966464 hasAuthorship W2109966464A5051594076 @default.
• W2109966464 hasBestOaLocation W21099664641 @default.
• W2109966464 hasConcept C106812560 @default.
• W2109966464 hasConcept C120770815 @default.
• W2109966464 hasConcept C126322002 @default.
• W2109966464 hasConcept C134018914 @default.
• W2109966464 hasConcept C181389837 @default.
• W2109966464 hasConcept C185592680 @default.
• W2109966464 hasConcept C2777622882 @default.
• W2109966464 hasConcept C2778326061 @default.
• W2109966464 hasConcept C2779698670 @default.
• W2109966464 hasConcept C2779959927 @default.
• W2109966464 hasConcept C2780189551 @default.
• W2109966464 hasConcept C2780394083 @default.
• W2109966464 hasConcept C2780521442 @default.
• W2109966464 hasConcept C519581460 @default.
• W2109966464 hasConcept C71924100 @default.
• W2109966464 hasConcept C84393581 @default.
• W2109966464 hasConcept C98274493 @default.
• W2109966464 hasConceptScore W2109966464C106812560 @default.
• W2109966464 hasConceptScore W2109966464C120770815 @default.
• W2109966464 hasConceptScore W2109966464C126322002 @default.
• W2109966464 hasConceptScore W2109966464C134018914 @default.
• W2109966464 hasConceptScore W2109966464C181389837 @default.
• W2109966464 hasConceptScore W2109966464C185592680 @default.
• W2109966464 hasConceptScore W2109966464C2777622882 @default.
• W2109966464 hasConceptScore W2109966464C2778326061 @default.
• W2109966464 hasConceptScore W2109966464C2779698670 @default.
• W2109966464 hasConceptScore W2109966464C2779959927 @default.
• W2109966464 hasConceptScore W2109966464C2780189551 @default.
• W2109966464 hasConceptScore W2109966464C2780394083 @default.
• W2109966464 hasConceptScore W2109966464C2780521442 @default.
• W2109966464 hasConceptScore W2109966464C519581460 @default.
• W2109966464 hasConceptScore W2109966464C71924100 @default.
• W2109966464 hasConceptScore W2109966464C84393581 @default.
• W2109966464 hasConceptScore W2109966464C98274493 @default.
• W2109966464 hasIssue "2" @default.
• W2109966464 hasLocation W21099664641 @default.
• W2109966464 hasLocation W21099664642 @default.
• W2109966464 hasOpenAccess W2109966464 @default.
• W2109966464 hasPrimaryLocation W21099664641 @default.
• W2109966464 hasRelatedWork W1990346928 @default.
• W2109966464 hasRelatedWork W2019650760 @default.
• W2109966464 hasRelatedWork W2066360730 @default.
• W2109966464 hasRelatedWork W2074042972 @default.
• W2109966464 hasRelatedWork W2126050374 @default.
• W2109966464 hasRelatedWork W2139541900 @default.
• W2109966464 hasRelatedWork W2249728733 @default.
• W2109966464 hasRelatedWork W2284947444 @default.
• W2109966464 hasRelatedWork W2743038916 @default.
• W2109966464 hasRelatedWork W3030505798 @default.
• W2109966464 hasVolume "14" @default.
• W2109966464 isParatext "false" @default.
• W2109966464 isRetracted "false" @default.
• W2109966464 magId "2109966464" @default.
• W2109966464 workType "article" @default.